The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials (NCT05203172)
ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they have not enrolled in a prior study of encorafenib or binimetinib. Participants that had enrolled but had stopped receiving the study treatment in a prior study cannot enrolled in this study. Participants in the FLOTILLA study will receive encorafenib and/or binimetinib at the same dose and frequency as in their prior study, for up to about 5 years.
Who can join: Review the eligibility criteria below.
Location: St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (67 Sites)
Showing the first 25 of 67 sites.
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Investigational Drug Service Emory University Clinic — Atlanta, Georgia
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- HealthPartners Cancer Research Center — Saint Paul, Minnesota
- Regions Hospital Pharmacy — Saint Paul, Minnesota
- Siteman Cancer Center — St Louis, Missouri
- Barnes-Jewish Hospital — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Washington University — St Louis, Missouri
- MSK Basking Ridge — Basking Ridge, New Jersey
- Rockefeller Outpatient Pavilion (53rd Street) — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke Cancer Center — Durham, North Carolina
- Investigational Chemotherapy Service — Durham, North Carolina
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Liga Norte Riograndense Contra o Câncer — Natal, Rio Grande do Norte
- ONCOSITE - Centro de Pesquisa Clinica em Oncologia — Ijuí, Rio Grande do Sul
- Fundação Pio XII - Hospital de Câncer de Barretos — Barretos, São Paulo
- BP - A Beneficencia Portuguesa de São Paulo — São Paulo, São Paulo
- Real e Benemerita Associacao Portuguesa de Beneficencia — São Paulo, São Paulo
- University Health Network — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.